The Healthtech Muster: FocalPoint

​Tenmile cordially invites you to our inaugural health innovation forum and celebration - The Healthtech Muster!

Australia has great things happening in health and life sciences. Yet much of it is hidden away, with limited visibility and fun opportunities to engage with the latest innovations and high calibre individuals who make things happen.

So, we're bringing together a curated group of Australia’s best minds in health and biotech, from all parts of our vibrant ecosystem. Along with global leaders to celebrate and spotlight the latest innovations, issues and implications of happenings in Australia's health ecosystem. To help connect, elevate and showcase t wonderful health innovation community.

During this exclusive afternoon of programming, you’ll hear from and engage with the likes of:

• Reed Jobs, Founder of Yosemite Ventures & Managing Director of Emerson Collective
• Alice Zhang, Co-founder & CEO of Verge Genomics
• A rapid fire showcase of leading research coming out of Australia
• Engage in some lively expert led discussions

The day program will run from 1pm - 5.30pm.

Followed by a Healthtech networking session with the broader Healthtech community.

This is one not to be missed and invite only. And we would love for you to join us.

Please RSVP below as spots are limited. Or, if you can't make it but have a colleague you could recommend, please let us know.

​Stay tuned for more details soon!

​Team Tenmile

------------------

A bit about some of our speakers...

Reed Jobs,
Founder of Yosemite Ventures & Managing Director of Emerson Collective

Reed and his team launched Yosemite in August 2023 to make cancer nonlethal in our lifetime. Yosemite works in late-stage academic research and for-profit company creation to invest in the most promising science from across the world to achieve this mission. Prior to starting Yosemite, Reed was the Managing Director of Health at Emerson Collective for eight years. Reed holds a B.A. in history and international security and an M.A. in history, both from Stanford University.

Alice Zhang,
Co-founder & CEO of Verge Genomics

Alice Zhang is the CEO and Co-founder of Verge Genomics. Verge Genomics uses artificial intelligence to develop better drugs, faster for diseases like ALS, Parkinson’s Disease, and Alzheimer’s Disease. Alice has been recognized for her work as a Forbes 30 Under 30 Featured Honoree, MIT Technology Review’s Innovator Under 35, SF Business Times’ 40 Under 40, and Business Insider's 2023 feature of 30 People Under 40 Transforming Healthcare.She currently sits on the board of directors at the California Life Sciences Association. Prior to Verge, she spent five years in the UCLA-Caltech MD/PhD program and received her BA degree from Princeton University in Molecular Biology. In her spare time, Alice also is an angel investor and advisor for tech-enabled bio startups.

Dr. Arjun Goyal,
Co-Founder and Managing Director of Vida Ventures

Dr. Arjun Goyal is a Co-Founder and Managing Director of Vida Ventures, a leading US-based life sciences venture capital firm with a ~$1.8 billion in AUM. Arjun focuses on creating and investing in companies that translate groundbreaking science into innovative medicines. 

Arjun serves as a director on the boards of Scorpion Therapeutics, Quanta Therapeutics, Alterome Therapeutics, Halda Therapeutics, Third Arc Bio, and Centessa Pharmaceuticals (NASDAQ: CNTA) and as a co-founder and director, Affini-T Therapeutics. Furthermore, he has played key roles in Vida Venture’s investments in Homology Medicines (NASDAQ:FIXX), Pionyr Immunotherapeutics (acquired by Gilead), Peloton Therapeutics (acquired by Merck & Co.), and Asklepios Bio (acquired by Bayer). 
 
Before co-founding Vida Ventures in 2017, Arjun was a life sciences investor at 5AM Ventures. Arjun his B.Sc. in Medical Science, Diploma in French and his MBBS degree from the Universities of Melbourne and Oxford. He completed his postgraduate clinical training in Internal Medicine in Sydney. He received his M.Phil. in Bioscience Enterprise from University of Cambridge and his MBA from Harvard Business School. Arjun has received multiple awards for his work including the Advance Award for Technology & Entrepreneurship from the Australian Government. He serves on the Committee for the American Australian Association Education Fellowship and is on the Board of Advisors of the MS/MBA Life Sciences Program at Harvard Business School where also serves as a Venture Capital Advisor

Liz Dallimore,
CEO & Managing Director of Argenica Therapeutics

Liz is the CEO & Managing Director of Argenica Therapeutics (ASX:AGN), a clinical stage company developing therapies to treat neurological conditions. Liz has deep experience in both biotechnology and management consulting with over 20 years’ experience across Australia and the UK, previously as KPMG’s National Director of Research Engagement and Commercialisation, as well as holding senior roles with Ernst & Young and PricewaterhouseCoopers. 

Liz also sits on the Board of AusBiotech, Australia’s biotechnology peak industry body and is the co-founder and Executive Chairman of medical device company Inspiring Holdings Pty Ltd. Liz was named a winner in Women in Technology WA Tech Awards in 2019 and selected as one of 25 Australian Female Leaders in STEM for the 2022 Federal Government’s inaugural WILD program. Liz holds a PhD in neuroscience from Oxford University and the University of Western Australia, an MBA in Innovation & Technology from the Australian Graduate School of Management and is a Member of the Australian Institute of Company Directors.

Steve Burnell,
Managing Director of Tenmile

Steve is the Managing Director of Tenmile an Australian HealthTech venture capital company owned by Tattarang one of Australia's largest private companies. Steve's professional experience spans research, philanthropy, strategy consulting, M&A, and operating global businesses in fields as diverse as marine ecology, digital health, and precision oncology. 

He is relentlessly passionate about the power of new technology to positively impact human health and mitigate our climate impacts. Prior to his current role, Steve managed a global business, led M&A and established a new informatics and real-world data business for the world's largest biotech, Roche-Genentech. He remains a strategic advisor to Minderoo Foundation where he has led initiatives focused on COVID-19, Cancer, and Ocean Genomics amongst others. He holds a B.Sc. (Hons.) in Biology and a Ph.D. in Population Biology from the University of Sydney.